Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study

Figure 1

Kaplan-Meier survival curves demonstrating trend towards increased colectomy (a, ) and UC-related hospitalization (b, ) rate during maintenance infliximab or adalimumab for 57 ulcerative colitis patients starting anti-TNF therapy within three years of diagnosis (blue) compared to 57 patients starting anti-TNF therapy more than three years after diagnosis (red). There is no difference in secondary loss of response requiring dose escalation between early and late anti-TNF initiators (c, ). Hashed lines indicate censored cases (which did not meet primary outcome to last follow-up).

(a)

(b)

(c)